Placeholder Banner

BIO Commends the Introduction of the Helping Startups Continue to Grow Act

October 30, 2019

In a recent letter, BIO’s Jim Greenwood commended Representative Steil (R-WI) for introducing the “Helping Startups Continue to Grow Act,” which extends the exemption afforded to Emerging Growth Companies under the JOBS Act from certain executive compensation, financial, and other disclosure requirements for an additional five years.

“As helpful as this five-year exemption is, the biotech development timeline takes a decade or more. Emerging biotechs companies working on innovative therapeutics are highly dependent on access to capital during this time. Developing a single therapy requires an average investment of more than $2 billion. During this development stage, companies do not have a product to generate revenue and are dependent on capital markets to fund clinical trials. Every dollar spent on regulatory burdens that do not provide useful information to investors is therefore a dollar diverted from the lab. A five-year extension of EGC provisions will enable small public biotechs to continue to prioritize research and innovation, and will free up more capital to hire scientific and technical talent, invest further in R&D and clinical development, and enhance their ability deliver product candidates to patients suffering from various diseases,” Greenwood wrote.

To read the full letter below.

Download Full Comments Below
Helping Startups Continue to Grow Act

BIO sent a letter to Representative Brian Steil to support the "Helping Startups Continue to Grow Act."

Discover More
We write as a coalition of advocates for the startup ecosystem to voice our strong support for the IGNITE American Innovation Act, legislation to support startups through the economic crisis by allowing companies to monetize tax assets generated…
July 31, 2020 Re: Docket No. FDA–2020-N-0837: Raare Disease Clinical Trial Network; Request for Information. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency) for the…
July 30, 2020 Re: Docket No. FDA–2019-D-5799: FDA’s Public Meeting, Modernizing the Food and Drug Administration’s Data Strategy. Dear Sir/Madam: The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or…